BioArctic
Bristol Myers Squibb Partners with BioArctic in $100M Alzheimer’s Deal
Bristol Myers Squibb, BioArctic, Leqembi, Alzheimer’s disease, collaboration, $100M upfront payment
Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803